Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy

Psychosomatic Medicine

Volumn 70, Issue 3, 2008, Pages 319-327

  Bruce, Erica C ^a   Guo, Ying ^b   Lawson, Kathryn C ^a   Manatunga, Amita K ^b   Auyeung, S Freda ^a   McDonald, William M ^a   Rushing, Natasha ^a   Brown, Angelo R ^a   Gilles, Natalie ^a   Emery, Milburn ^a   Bonsall, Robert ^a   Porquez, Jocelyn ^a   Stowe, Zachary ^a   Nemeroff, Charles B ^a   Musselman, Dominique L ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Antidepressants; Autocrine pathways; Electroconvulsive therapy; Major depressive disorder; Platelet function; Thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; LITHIUM; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THROMBOXANE A2;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; METABOLITE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SYMPTOM; THERAPY EFFECT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT PLANNING; TREATMENT RESPONSE; URINE LEVEL;

EID: 42149147869     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/PSY.0b013e3181663580     Document Type: Article

References (57)

1. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert L. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000;157:1006-8.
2. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-7.
3. Whyte EM, Pollock BG, Wagner WR, Mulsant BH, Ferrell RE, Mazumdar S, Reynolds CF 3rd. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001;158:2074-6.
4. Piletz JE, Zhu H, Madakasira S, Pazzaglia P, Lindsay DeVane C, Goldman N, Halaris A. Elevated P-selectin on platelets in depression: response to bupropion. J Psychiatr Res 2000;34:397-404.
5. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan RR, Gaffney M, Harrison W, Califf RM, O'Connor CM, Sertraline AntiDepressant Heart Attack Randomized Trial Study Group. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the sertraline antidepressant heart attack randomized trial (SADHART) platelet substudy. Circulation 2003;108:939-44.
6. Kuijpers PM, Hamulyak K, Strik JJ, Wellens HJ, Honig A. Beta-thromboglobulin and platelet factor 4 levels in post-myocardial infarction patients with major depression. Psychiatry Res 2002;109:207-10.
7. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983;67:1174-7.
8. Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT, Hanson SR, Nemeroff CB. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57:875-82.
9. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and b-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-5.
10. Musselman DL, Marzec U, Davidoff M, Manatunga AK, Gao F, Reemsnyder A, Dugggirala S, Knight BT, Taylor RW, Hanson S, Nemeroff CB. Platelet activation and secretion in patients with major depression compared to patients with atherosclerosis or renal dialysis treatment. Depression 2002;15:91-101.
11. Fimognari FL, Piccirillo G, Lama J, Paganica P, Monteleone G, Gianni W, Cacciafesta M, Marigliano V. Associated daily biosynthesis of cortisol and thromboxane A2: a preliminary report. J Lab Clin Med 1996;128:115-21.
12. 2 formation in the human circulation. Proc Natl Acad Sci U S A 1986;83:5861-5.
13. Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA. Analysis of multiple thromboxane metabolites in plasma and urine. Adv Prostaglandin Thromboxane Leukot Res 1987;17B:611-4.
14. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975;72:2994-8.
15. Needleman P, Minkes M, Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science 1976;193:163-5.
16. Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD. Effect of strenuous exercise on platelet activation state and reactivity. Circulation 1993;88:1502-11.
17. Kratz A, Wood MJ, Siegel AJ, Hiers JR, Van Cott EM. Effects of marathon running on platelet activation markers: direct evidence for in vivo platelet activation. Am J Clin Pathol 2006;125:296-300.
18. Terres W, Weber K, Kupper W, Bleifeld W. Age, cardiovascular risk factors and coronary heart disease as determinants of platelet function in men. A multivariate approach. Thromb Res 1991;62:649-61.
19. Coppola L, Grassia A, Coppola A, Tondi G, Peluso G, Mordente S, Gombos G. Effects of a moderate-intensity aerobic program on blood viscosity, platelet aggregation and fibrinolytic balance in young and middle-aged sedentary subjects. Blood Coagul Fibrinolysis 2004;15:31-7.
20. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002;288:2008-14.
21. Coppola A, Coppola L, dalla Mora L, Limongelli FM, Grassia A, Mastrolorenzo L, Gombos G, Lucivero G. Vigorous exercise acutely changes platelet and B-lymphocyte CD39 expression. J Appl Physiol 2005;98:1414-9.
22. Dunn AL, Trivedi MH, O'Neal HA. Physical activity dose-response effects on outcomes of depression and anxiety. Med Sci Sports Exerc 2001;33:S587- S597;discussion S609-S610.
23. Ersoz G, Zergeroglu AM, Ficicilar H, Ozcan H, Oztekin P, Aytac S, Yavuzer S. Effect of submaximal and incremental upper extremity exercise on platelet function and the role of blood shear stress. Thromb Res 2002;108:297-301.
24. Mikhailidis DP, Barradas MA, Mier A, Boag F, Jeremy JY, Havard CW, Dandona P. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology 1987;38:36-45.
25. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
26. 2 in depression. Prostaglandins Leukot Med 1983;10:361-7.
27. 2 in patients with depression. Am J Med Sci 1994;307:228-32.
28. Association AP. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association;2000.
29. American Psychiatric Association Task Force on Electroconvulsive Therapy: The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. Washington, DC: American Psychiatric Association Press;2001.
30. Spitzer RL. Psychiatric diagnosis: are clinicians still necessary? Compr Psychiatry 1983;24:399-411.
31. Beck AT, Steer RA, Ranieri WF. Comparison of Beck depression inventories-IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-97.
32. 2 stimulation in patients with major depression. Annual Meeting of the American Psychosomatics Society. Orlando, Florida, 2004.
33. Jafri SM, VanRollins M, Ozawa T, Mammen EF, Goldberg AD, Goldstein S. Circadian variation in platelet function in healthy volunteers. Am J Cardiol 1992;69:951-4.
34. Garde AH, Hansen AM, Kristiansen J, Knudsen LE. Comparison of uncertainties related to standardization of urine samples with volume and creatinine concentration. Ann Occup Hyg 2004;48:171-9.
35. Figiel G, McDonald WM, McCall WV, Zorumpski C. Electroconvulsive therapy. In: Schatzberg AF, Nemeroff CB, editors. American Psychiatric Association Textbook of Psychopharmacology. Washington, DC: American Psychiatric Association; 1998.
36. Coffey CE, Weiner RD, Hinkle PE, Cress M, Daughtry G, Wilson WH. Augmentation of ECT seizures with caffeine. Biol Psychiatry 1987;22:637-49. Erratum in Biol Psychiatry 1987;22:1299.
37. Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. Edinburgh, Scotland: Churchill Livingstone; 1983.
38. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-40.
39. Todd MK, Goldfarb AH, Boyer BT. Effect of exercise intensity on 6-keto-PGF1 alpha, TXB2, and 6-keto-PGF1 alpha/TXB2 ratios. Thromb Res 1992;65:487-93.
40. Galper DI, Trivedi MH, Barlow CE, Dunn AL, Kampert JB. Inverse association between physical inactivity and mental health in men and women. Med Sci Sports Exerc 2006;38:173-8.
41. Brown DW, Balluz LS, Heath GW, Moriarty DG, Ford ES, Giles WH, Mokdad AH. Associations between recommended levels of physical activity and health-related quality of life. Findings from the 2001 behavioral risk factor surveillance system (BRFSS) survey. Prev Med 2003;37:520-8.
42. Goodwin RD. Association between physical activity and mental disorders among adults in the United States. Prev Med 2003;36:698-703.
43. U.S. Department of Health and Human Services: Physical Activity and Health: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
44. Reilly IA, FitzGerald GA. Eicosenoid biosynthesis and platelet function with advancing age. Thromb Res 1986;41:545-54.
45. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105.
46. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998;338:1-7.
47. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997;96:3248-50.
48. Van Nueten JM, Janssen PAJ, Fitzgerald C. Ketanserin. New Cardiovascular Drugs 1987;1-56.
49. De Clerck F, de Chaffoy de Courcelles D. Amplification mechanisms in platelet activation. Atherosclerosis Reviews 1989;19:105-40.
50. DeClerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991;17(Suppl 5):S1-S5.
51. Weyrich AS, Solis GA, Li KS, Tulenko TN, Santamore WP. Platelet amplification of vasospasm. Am J Physiol 1992;263:H349-H358.
52. Bruno A, McConnell JP, Mansbach HH, Cohen SN, Tietjen GE, Bang NU. Aspirin and urinary 11-dehydrothromboxane B2 in African American stroke patients. Stroke 2001;53:57-60.
53. Stain-Malmgren R, Tham A, Aberg-Wistedt A. Increased platelet 5-HT2 receptor binding after electroconvulsive therapy in depression. J ECT 1998;14:15-24.
54. Werstiuk ES, Coote M, Griffith L, Shannon H, Steiner M. Effects of electroconvulsive therapy on peripheral adrenoceptors, plasma, noradrenaline, MHPG and cortisol in depressed patients. Br J Psychiatry 1996;169:758-65.
55. Theodorou AE, Lawrence KM, Healy D, Whitehouse AM, White W, Wilton-Cox H, Kerry SM, Horton RW, Paykel ES. Platelet alpha 2-adrenoceptors, defined with agonist and antagonist ligands, in depressed patients, prior to and following treatment. J Affect Disord 1991;23:99-106.
56. De Abajo FJ, Rodriguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999;319:1106-9.
57. Van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001;323:655-61.